As the US stock market faces its largest decline in four years, any investment on Wall Street will be increasingly risky. However, there is no denying that currency price levels provide a key entry point for traders. With Microsoft (MSFT) dropping to $380, is potential 70% upside with the risk?

There are a lot of reasons for investors to be excited about what Microsoft has done. Moreover, it didn’t fall as much as companies like Tesla (TSLA) did, with the EV manufacturer dropping a remarkable 16% on Monday. Still, is investing in the Windows developer worth the risk that is present in any stock market investment right now?

Also Read: Microsoft Developing Its Own AI: Can MSFT Stock Lead Market?

Microsoft Stock Falls to $380 as Upside May Be Worth Navigating Market Risk

On a horrid Monday that saw the US stock market perform its worst in more than four years, Microsoft (MSFT) dropped just 3%. Although a notable decline, it was far less concerning than other companies navigated. The question now is whether or not the company is a smart play for anxious investors.

There are struggles abiding Wall Street that are undeniable. However, with the risks may come many rewards. Subsequently, many are facing the issue of whether or not Microsoft (MSFT) is worth buying at $380, amid increased investment risk due to its 70% upside.

Also Read: Microsoft (MSFT) Stock a Billionaire Favorite, Surpassing Nvidia

Microsoft has been a revenue growth machine in recent years. Specifically, the company has seen its top line increase at a rate of 13.5% over the last three years, according to Forbes. That is greater than the S&P 500, whose growth rate is just 6.9%. Additionally, revenue jumped 15% in the last year, with the S&P 500 growing 5.3%.

On a quarterly basis, that growth also continued, jumping 12% versus a year ago, again outperforming the S&P 500. What makes this entry point so interesting is what experts are projecting for the company.

Microsoft currently has a media price target of $500, according to CNN. Up 30% from its current poison, that pales in comparison to its high-end price projection. Specifically, it is forecasted to reach $650, with a 70% upside in the best case over the next 12 months. Moreover, of 57 surveyed analysts, 93% have issued a buy rating on the stock.